All Stories

  1. Parsing heterogeneity in global and local white matter integrity at different stages across the psychosis continuum
  2. Breaking barriers in the career development of women in academic psychiatry
  3. Parsing heterogeneity in global and local white matter integrity at different stages across the psychosis continuum
  4. The role of gender as a barrier to the professional development of psychiatrists
  5. Impact of adverse childhood experiences on educational achievements in young people at clinical high risk of developing psychosis
  6. Latent state-trait structure of BPRS subscales in clinical high-risk state and first episode psychosis
  7. Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis
  8. Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis
  9. Dysregulated Lipid Metabolism Precedes Onset of Psychosis
  10. Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With Clinical High-Risk Syndromes and Recent-Onset Depression
  11. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings
  12. The association between migrant status and transition in an ultra-high risk for psychosis population
  13. Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence
  14. Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people
  15. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis
  16. EEG Microstate Differences in Medicated vs. Medication-Naïve First-Episode Psychosis Patients
  17. Basic Symptoms Are Associated With Age in Patients With a Clinical High-Risk State for Psychosis: Results From the PRONIA Study
  18. Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis
  19. Editorial
  20. Omega‐3 fatty acids and neurocognitive ability in young people at ultra‐high risk for psychosis
  21. EEG microstates as biomarker for psychosis in ultra-high-risk patients
  22. Prediction of clinical outcomes beyond psychosis in the ultra‐high risk for psychosis population
  23. Corrigendum: Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
  24. Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?
  25. Anatomical integrity within the inferior fronto-occipital fasciculus and semantic processing deficits in schizophrenia spectrum disorders
  26. Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial
  27. Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis
  28. Dysregulated lipid metabolism precedes onset of psychosis in people at clinical high risk
  29. Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis
  30. Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes
  31. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis
  32. Sex differences in cognitive functioning of patients at-risk for psychosis and healthy controls: Results from the European Gene–Environment Interactions study
  33. Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial
  34. Individualized prediction of psychosis in subjects with an at-risk mental state
  35. Predictors of study drop-out and service disengagement in patients at clinical high risk for psychosis
  36. An overlapping pattern of cerebral cortical thinning is associated with both positive symptoms and aggression in schizophrenia via the ENIGMA consortium
  37. Clinical and functional ultra-long-term outcome of patients with a clinical high risk (CHR) for psychosis
  38. Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review
  39. Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk
  40. Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach
  41. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial
  42. Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study
  43. Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis
  44. No associations between medial temporal lobe volumes and verbal learning/memory in emerging psychosis
  45. Correction
  46. Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?
  47. Estrogens and SERMS as adjunctive treatments for schizophrenia
  48. O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY
  49. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial
  50. Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status
  51. Bride price payment and women’s autonomy: Findings from qualitative interviews from Nigeria
  52. WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women
  53. Dynamic prediction of transition to psychosis using joint modelling
  54. Voxel-Based Morphometry Correlates of an Agitated-Aggressive Syndrome in the At-Risk Mental State for Psychosis and First Episode Psychosis
  55. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium
  56. Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression
  57. The relationship between negative symptoms and cognitive functioning in patients at clinical high risk for psychosis
  58. Sexually dimorphic subcortical brain volumes in emerging psychosis
  59. Can neuropsychological testing facilitate differential diagnosis between at-risk mental state (ARMS) for psychosis and adult attention-deficit/hyperactivity disorder (ADHD)?
  60. Exploring the predictive power of the unspecific risk category of the Basel Screening Instrument for Psychosis
  61. Clinical trajectories in the ultra-high risk for psychosis population
  62. Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients
  63. NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course
  64. Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in at-risk mental state and first-episode psychosis
  65. Disorganized Gyrification Network Properties During the Transition to Psychosis
  66. Sex and gender differences in schizophrenic psychoses—a critical review
  67. Evaluating verbal learning and memory in patients with an at-risk mental state or first episode psychosis using structural equation modelling
  68. The neuropsychology of emerging psychosis and the role of working memory in episodic memory encoding
  69. T212. THE INTRINSIC ORGANIZATION OF SYMPTOMS MARKS TRANSITION FROM HIGH-RISK STATE TO EARLY PSYCHOSIS: A PHENOMENOLOGICAL CONNECTIVITY STUDY
  70. O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL
  71. S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING
  72. T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY
  73. T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION
  74. Abnormal brain connectivity during error-monitoring in the psychosis high-risk state
  75. Letter from the Editor-in-Chief
  76. Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume
  77. The Frankfurt Complaint Questionnaire for self-assessment of basic symptoms in the early detection of psychosis-Factor structure, reliability, and predictive validity
  78. Gender differences in first self‐perceived signs and symptoms in patients with an at‐risk mental state and first‐episode psychosis
  79. Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in women
  80. Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients
  81. Age-related brain structural alterations as an intermediate phenotype of psychosis
  82. Duration of untreated psychosis/illness and brain volume changes in early psychosis
  83. Patient-Identified Priorities Leading to Attempted Suicide
  84. Screening for Adult Attention-Deficit/Hyperactivity Disorder in a Psychiatric Outpatient Population with Specific Focus on Sex Differences
  85. Alpha oscillations underlie working memory abnormalities in the psychosis high-risk state
  86. Prediction of conversion to psychosis in individuals with an at-risk mental state
  87. Outcome of individuals “not at risk of psychosis” and prognostic accuracy of the Basel Screening Instrument for Psychosis (BSIP)
  88. Comorbidities in Patients with an At-risk Mental State and First Episode Psychosis
  89. Estradiol Production Suppressed by Prolactin in at-risk Mental State and First Episode Psychosis Female Patients? Preliminary Results
  90. Long-term rates of remission and late psychotic transition of individuals at risk for psychosis
  91. Stigma in early detection of psychosis: Subjective experiences of those concerned
  92. The Current European Status
  93. The Relationship Between Negative Symptoms and Cognitive Functioning in Patients with an at Risk Mental State for Psychosis
  94. Verbal Learning and Memory in At-risk Mental State and First Episode Psychosis Patients and Their Correlates to Brain Structural Alterations
  95. Working Together for Early Detection of Psychosis
  96. Autonomy and Reproductive Rights of Married Ikwerre Women in Rivers State, Nigeria
  97. Letter from the Editor-in-Chief
  98. Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting
  99. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders
  100. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses
  101. Sex and gender differences in mental disorders
  102. Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis
  103. Altered Insular Function during Aberrant Salience Processing in Relation to the Severity of Psychotic Symptoms
  104. Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders
  105. Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis
  106. Pourquoi et comment soigner plus précocement les troubles psychotiques ?
  107. Alterations in the hippocampus and thalamus in individuals at high risk for psychosis
  108. Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis
  109. Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms
  110. Impact of polygenic schizophrenia-related risk and hippocampal volumes on the onset of psychosis
  111. Does menopausal transition really influence mental health? Findings from the prospective long-term Zurich study
  112. High time for a paradigm shift in psychiatry
  113. Neural oscillations in antipsychotic-naïve patients with a first psychotic episode
  114. Longitudinal determinants of client treatment satisfaction in an intensive first-episode psychosis treatment programme
  115. The role of vulnerability factors in individuals with an at-risk mental state of psychosis
  116. Early psychosis in young women
  117. Sex and gender differences in schizophrenic psychoses
  118. Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk
  119. Appropriateness of Care and Joint Decision-Making Strategies
  120. Menopause and Mental Health
  121. The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis
  122. Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naïve at-risk patients
  123. Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment
  124. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction
  125. Correlations between self-rating and observer-rating of psychopathology in at-risk mental state and first-episode psychosis patients: influence of disease stage and gender
  126. Early detection of psychosis: helpful or stigmatizing experience? A qualitative study
  127. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders
  128. Modulation of motivational salience processing during the early stages of psychosis
  129. Depression in der Peripartalzeit – Diagnostik, Therapie und Prophylaxe
  130. Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers
  131. EPA guidance on the early detection of clinical high risk states of psychoses
  132. EPA guidance on the early intervention in clinical high risk states of psychoses
  133. Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution
  134. Das Basler Interview für Psychosen (BIP): Struktur, Reliabilität und Validität
  135. Perinatal mental health service provision in Switzerland and in the UK
  136. Autism Spectrum Disorders
  137. Therapist-client sex in psychotherapy: attitudes of professionals and students towards ethical arguments
  138. Sex Differences in Cognitive Functioning in At-Risk Mental State for Psychosis, First Episode Psychosis and Healthy Control Subjects
  139. Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing
  140. Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication
  141. Brain Diffusion Changes in Emerging Psychosis and the Impact of State-Dependent Psychopathology
  142. Früherkennung und Frühintervention bei beginnenden Psychosen
  143. Comorbidity of Mental and Physical Disorders
  144. Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity
  145. Aberrant Current Source-Density and Lagged Phase Synchronization of Neural Oscillations as Markers for Emerging Psychosis
  146. Acute Effects of Heroin on Negative Emotional Processing: Relation of Amygdala Activity and Stress-Related Responses
  147. Evidence for an agitated–aggressive syndrome predating the onset of psychosis
  148. Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state
  149. Detecting the Psychosis Prodrome Across High-Risk Populations Using Neuroanatomical Biomarkers
  150. Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations
  151. Effects of heroin
  152. Poster #S162 DEFICITS IN FINE MOTOR SKILLS IN EMERGING PSYCHOSIS
  153. Poster #M222 PSYCHOSIS EARLY DETECTION: HELPFUL OR STIGMATIZING EXPERIENCE? A QUALITATIVE PILOT STUDY
  154. Poster #S147 EYE MOVEMENT ABNORMALITIES IN ADULTS WITH AN AT-RISK MENTAL STATE FOR PSYCHOSIS
  155. HELP-SEEKING AND PATHWAYS TO CARE IN THE EARLY STAGES OF PSYCHOSIS: RESULTS FROM THE FEPSY STUDY
  156. Poster #T189 DEVIANT NEURAL OSCILLATIONS AND LAGGED PHASE SYNCHRONICITY IN PATIENTS WITH AN AT-RISK MENTAL STATE FOR PSYCHOSIS
  157. Poster #M40 THE RELATION OF ABNORMAL BRAIN CONNECTIVITY AND PSYCHIATRIC SYMPTOM EXPRESSION IN SUBJECTS AT HIGH-RISK FOR PSYCHOSIS
  158. Poster #T180 THE COURSE OF COGNITIVE FUNCTIONING IN CLINICAL HIGH RISK AND FIRST-EPISODE PSYCHOSIS INDIVIDUALS
  159. Poster #S109 THE BASEL INTERVIEW FOR PSYCHOSIS: STRUCTURE, RELIABILITY AND VALIDITY
  160. Poster #T220 TRANSITION AND PSYCHOSIS RELATED HEMODYNAMIC CORRELATES OF MOTIVATIONAL SALIENCE PROCESSING
  161. THE PSYCHOSIS HIGH RISK STATE: IS IT VALID?
  162. Schmidt a psychosis
  163. Pituitary gland volume in at-risk mental state for psychosis: a longitudinal MRI analysis
  164. The attenuated psychosis syndrome in DSM-5
  165. Are neurological soft signs pre-existing markers in individuals with an at-risk mental state for psychosis?
  166. Violence against women and mental health
  167. Cannabis use and brain structural alterations of the cingulate cortex in early psychosis
  168. Boothe B, Riecher-Rössler A (Hrsg) (2013) Frauen in Psychotherapie. Grundlagen – Störungsbilder – Behandlungskonzepte
  169. Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders
  170. Comentario de libro
  171. Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis
  172. S.10.03 Hyperprolactinemia in drug-naïve first-episode patients: data from EUFEST
  173. P.1.i.025 Abnormal brain functioning during salience processing in patients with schizophrenic psychosis
  174. P.6.d.001 Inhibition-specific prefrontal connectivity after an acute dose of heroin
  175. Reduction in Cerebral Perfusion after Heroin Administration: A Resting State Arterial Spin Labeling Study
  176. Brain Connectivity Abnormalities Predating the Onset of Psychosis
  177. Sollen junge Menschen mit Psychoserisikosyndrom behandelt werden?
  178. Häusliche Gewalt bei Frauen einer Kriseninterventionspopulation - Formen der Gewalt und Risikofaktoren
  179. Cannabis use and cognitive functions in at-risk mental state and first episode psychosis
  180. Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study
  181. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial
  182. Suicide attempts in the county of Basel: results from the WHO/EURO Multicentre Study on Suicidal Behaviour
  183. Vorhersage von Psychosen durch stufenweise Mehrebenenabklärung - Das Basler FePsy(Früherkennung von Psychosen)-Projekt
  184. Inferior Frontal Cortex Modulation with an Acute Dose of Heroin During Cognitive Control
  185. Reduced parahippocampal cortical thickness in subjects at ultra-high risk for psychosis
  186. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis
  187. Acute effects of heroin on emotions in heroin‐dependent patients
  188. Duration of untreated psychosis and cognitive functioning
  189. Acute Effects of Intravenous Heroin on the Hypothalamic-Pituitary-Adrenal Axis Response
  190. Insight and Hostility as Predictors and Correlates of Nonadherence in the European First Episode Schizophrenia Trial
  191. Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial
  192. Violence against Women and Mental Health
  193. Association of Frontal Gray Matter Volume and Cerebral Perfusion in Heroin Addiction: A Multimodal Neuroimaging Study
  194. The Psychosis High-Risk State
  195. 2710 – Gender Differences in the Psychopathology of Emerging Psychosis
  196. Do Subjects at Clinical High Risk for Psychosis Differ from those with a Genetic High Risk? - A Systematic Review of Structural and Functional Brain Abnormalities
  197. Help-seeking and pathways to care in the early stages of psychosis
  198. Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study
  199. Can cognitive deficits facilitate differential diagnosis between at‐risk mental state for psychosis and depressive disorders?
  200. Kann Cannabis das Risiko für schizophrene Psychosen erhöhen?
  201. Whither the Attenuated Psychosis Syndrome?
  202. P.2.a.018 Actigraphically measured poor sleep is related to cortisol awakening response and parenting stress in postpartum depression
  203. P.1.e.014 Hippocampal volume in individuals with an at-risk mental state: a longitudinal magnetic resonance imaging analysis
  204. Effects of Cannabis Use on Human Brain Structure in Psychosis: A Systematic Review Combining In Vivo Structural Neuroimaging and Post Mortem Studies
  205. Distinguishing Prodromal From First-Episode Psychosis Using Neuroanatomical Single-Subject Pattern Recognition
  206. Group Treatment for Depression in Mothers of Young Children Compared to Standard Individual Therapy
  207. Priorities for research in child maltreatment, intimate partner violence and resilience to violence exposures: results of an international Delphi consensus development process
  208. Cost of attempted suicide: a retrospective study of extent and associated factors
  209. Poster #54 PITUITARY GLAND VOLUME IN INDIVIDUALS WITH AN AT-RISK MENTAL STATE: A LONGITUDINAL MRI ANALYSIS
  210. Poster #43 NEGATIVE SYMPTOMS IN THE EARLY STAGES OF PSYCHOSIS ARE ASSOCIATED WITH CHANGES IN THE CINGULATE
  211. Poster #52 DURATION OF UNTREATED ILLNESS/PSYCHOSIS AND COGNITIVE FUNCTIONING
  212. Poster #236 LONGITUDINAL CHANGES OF PSYCHOPATHOLOGICAL SYMPTOMS IN AT-RISK MENTAL STATE (ARMS) INDIVIDUALS WITHOUT TRANSITION TO PSYCHOSIS
  213. Poster #56 INSULAR VOLUME ABNORMALITIES ASSOCIATED WITH DIFFERENT TRANSITION PROBABILITIES TO PSYCHOSIS – A VOXEL-BASED MORPHOMETRY STUDY
  214. Poster #51 CANNABIS USE AND BRAIN STRUCTURAL ALTERATIONS OF CINGULATE CORTEX AND HIPPOCAMPUS IN FIRST EPISODE PSYCHOSIS PATIENTS AND AT RISK MENTAL STATE SUBJECTS
  215. Poster #127 DO NEUROLOGICAL SOFT SIGNS IN AT-RISK MENTAL STATE INDIVIDUALS PREDICT TRANSITION TO FIRST EPISODE PSYCHOSIS?
  216. First self‐perceived signs and symptoms in emerging psychosis compared with depression
  217. Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study
  218. Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?
  219. Cingulate Volume Abnormalities in Emerging Psychosis
  220. Attempted Suicide in Immigrants from Turkey: A Comparison with Swiss Suicide Attempters
  221. The Impact of Diacetylmorphine on Hypothalamic-Pituitary-Adrenal Axis Activity and Heroin Craving in Heroin Dependence
  222. Themenschwerpunkt „Women‘s Mental Health“
  223. Depression und Psychose in der Menopause - kann eine Hormontherapie hilfreich sein?
  224. Insular volume abnormalities associated with different transition probabilities to psychosis
  225. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective
  226. Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study
  227. Different duration of at‐risk mental state associated with neurofunctional abnormalities. A multimodal imaging study
  228. Missbrauch in therapeutischen Beziehungen
  229. Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)
  230. Sexual Dysfunction in First-Episode Schizophrenia Patients
  231. Neuroanatomical Abnormalities That Predate the Onset of Psychosis
  232. Patienten mit intensivpflichtigen medikamentösen Suizidversuchen – Risikoprofil und Verlauf
  233. A Randomized, Double-Blind, Placebo-Controlled Study of Light Therapy for Antepartum Depression
  234. Stress reactivity in patients with drug dependence and personality disorders
  235. Missbrauch in therapeutischen Beziehungen
  236. 5 Psychosen in Schwangerschaft und Stillzeit
  237. 10 Psychopharmakotherapie in Schwangerschaft und Stillzeit
  238. 8 Depressionen in der Postpartalzeit
  239. 1 Depressionen in der Schwangerschaft
  240. 13 Lichttherapie bei Depressionen in der Schwangerschaft
  241. 12 Gruppentherapie für Mütter mit Depressionen
  242. Pituitary volume increase during emerging psychosis
  243. Depression in der Schwangerschaft
  244. Depression in der frühen Mutterschaft
  245. EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis
  246. The Self-screen-Prodrome as a short screening tool for pre-psychotic states
  247. Hyperprolactinaemia in early psychosis—not only due to antipsychotics
  248. Domestic violence against women: Definitions, epidemiology, risk factors and consequences
  249. Neuroimaging predictors of transition to psychosis—A systematic review and meta-analysis
  250. Neural effects of heroin — Relation to anxiety stress
  251. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study
  252. Prospects for the classification of mental disorders in women
  253. Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)
  254. QEEG SPECTRAL POWER AND NEGATIVE SYMPTOMS IN THE DETECTION OF BEGINNING PSYCHOSIS
  255. VERBAL EPISODIC MEMORY IN FIRST EPISODE AND AT RISK MENTAL STATE FOR PSYCHOSIS PATIENTS COMPARED TO DEPRESSIVE PATIENTS AND HEALTHY CONTROLS
  256. COMPARISON OF CLINICAL ROUTINE EEG AND QUANTITATIVE EEG IN FIRST EPISODE OF PSYCHOSIS AND AT-RISK MENTAL STATE INDIVIDUALS
  257. Antipsychotic Drug Treatment in First-Episode Psychosis
  258. P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis
  259. Schizophrenia in women
  260. Estrogens and Gonadal Function in Schizophrenia and Related Psychoses
  261. S25-03 - At Risk Mental State for Psychosis: Clinical Features and Natural Course
  262. PW01-21 - Poor Sleep is Related to Parenting Stress and Impaired Postpartum Bonding in Depressed Mothers
  263. Negative symptoms in neuroleptic-naïve patients with first-episode psychosis correlate with QEEG parameters
  264. Efficacy of Using Cognitive Status in Predicting Psychosis: A 7-Year Follow-Up
  265. Prediction of Caseness for Mental Pathology in Swiss Conscripts: The Self-Screen Prodrome
  266. Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study
  267. Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia
  268. 04. Differential correlation of EEG power and negative symptoms in patients with and without transition to psychosis
  269. 06. QEEG spectral power density changes in the early course of schizophrenia
  270. Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie
  271. Schwangerschaftsdepression und deren Behandlung
  272. Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?
  273. The Effects of Antipsychotics on the Brain: What Have We Learnt from Structural Imaging of Schizophrenia? – A Systematic Review
  274. Antipsychotika und Hyperprolaktinämie: Pathophysiologie, klinische Bedeutung, Abklärung und Therapie
  275. Intervention in Individuals at Ultra-High Risk for Psychosis
  276. Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)
  277. Correction
  278. The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?
  279. EEG: a helpful tool in the prediction of psychosis
  280. „Selbstscreen-Prodrom” – Ein Selbstbeurteilungsinstrument zur Früherkennung von psychischen Erkrankungen und Psychosen
  281. Psychotic Disorders and Menopause: The Untold Story
  282. Can Cortical Thickness Asymmetry Analysis Contribute to Detection of At-Risk Mental State and First-Episode Psychosis?: A Pilot Study
  283. Schizophrenia and Motherhood
  284. Treatment Options in Depression During the Postpartum
  285. Suizidversuche in der ersten und zweiten Generation der ImmigrantInnen aus der Türkei
  286. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis
  287. Elternschaft und Belastungserleben: Psychometrische Überprüfung des Parenting-Stress-Index (PSI) an einer deutschsprachigen Stichprobe
  288. Psychische Störungen in Zeiten hormoneller Umstellung bei Frauen – Eine selektive Übersicht
  289. STRATEGIES FOR IMPROVING THE PREDICTION OF PSYCHOSIS
  290. GRAY MATTER ABNORMALITIES AND COGNITIVE FUNCTION IN SUBJECTS AT RISK FOR PSYCHOSIS: LONGITUDINAL PERSPECTIVES
  291. CAN CORTICAL THICKNESS ANALYSIS IN AT RISK MENTAL STATE CONTRIBUTE TO EARLY DETECTION OF PSYCHOSIS?
  292. THE NEURAPRO (NORTH AMERICA, EUROPE, AUSTRALIA PRODROME) STUDY: A MULTICENTER RCT OF TREATMENT STRATEGIES FOR SYMPTOMATIC PATIENTS AT ULTRA-HIGH RISK FOR PROGRESSION TO SCHIZOPHRENIA AND RELATED DISORDERS. DESIGN AND STUDY PLAN
  293. Das Basel Screening Instrument für Psychosen (BSIP): Entwicklung, Aufbau, Reliabilität und Validität
  294. Insular pathology in the at-risk mental state
  295. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
  296. Nützen Behandlungsempfehlungen in psychiatrischen versicherungsrechtlichen Gutachten?
  297. Anterior and posterior cingulum abnormalities in the prodromal phase of schizophrenia
  298. 183 – The Basel Screening Instrument for Psychosis (BSIP) – predicitive validity and interrater reliability
  299. Anterior cingulate pathology in the prodromal stage of schizophrenia
  300. Geschlechtsspezifische Aspekte in der Psychotherapie
  301. Autorinnen und Autoren
  302. Screening Partnergewalt
  303. Neuropsychological deficits in individuals with an at risk mental state for psychosis — Working memory as a potential trait marker
  304. Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence
  305. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis
  306. The role of medication in suicide attempts in Switzerland
  307. Früherkennung schizophrener Psychosen bei Männern und Frauen
  308. Aneurysms of Pericallosal Cerebral Artery Haemorrhage with Consecutive Psychosis
  309. Cavum septum pellucidum in patients with first episode psychosis and individuals at high risk of psychosis
  310. Psychotic experiences in the general population: A twenty-year prospective community study
  311. Regional Gray Matter Volume Abnormalities in the At Risk Mental State
  312. Indication and impact of mentoring models
  313. Prospects for the classification of mental disorders in women
  314. Association of regional grey matter abnormalities with cognitive functions in the at risk mental state
  315. Cognitive capability of individuals at risk with and without transition to psychosis
  316. Akute Psychose
  317. Schizophrenie und verwandte Erkrankungen
  318. Akut- und Notfallpsychiatrie – Wo werden die Betroffenen behandelt?
  319. TC12C THE FEPSY (EARLY DETECTION OF PSYCHOSIS) STUDY – TRANSITION RATES AND PREDICTORS OF PSYCHOSIS
  320. 0352 FIRST SIGNS AND SYMPTOMS IN INDIVIDUALS AT RISK FOR PSYCHOSIS AND PATIENTS WITH A FIRST EPISODE OF PSYCHOSIS
  321. WC4G GREY MATTER ABNORMALITIES IN PEOPLE WITH AN AT RISK MENTAL STATE — CROSS-SECTIONAL AND LONGITUDINAL DATA
  322. Oestrogen-A Protective Factor in Schizophrenia?
  323. The Basel early‐detection‐of‐psychosis (FEPSY)‐study – design and preliminary results
  324. Radiological findings in individuals at high risk of psychosis
  325. Early detection and treatment of schizophrenia: how early?
  326. Postpartale Depression
  327. Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable
  328. Book review
  329. Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia
  330. Buchbesprechung
  331. The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
  332. Size of burden of schizophrenia and psychotic disorders
  333. Werden psychisch Kranke zu schnell in die Rente „abgeschoben”?
  334. Estrogen Effects in Psychiatric Disorders
  335. Group Psychotherapy for Depression in Early Stages of Motherhood
  336. Diagnostic Classification of Perinatal Mood Disorders
  337. Chronisch subdurales Hämatom bei einem Patienten mit Verdacht auf Prodromalstadium einer Schizophrenie
  338. Geschlechtersensible Betreuungsansätze
  339. Behandlungsprobleme bei schizophrenen Störungen
  340. Late-Onset Schizophrenia Versus Paranoid Psychoses: A Valid Diagnostic Distinction?
  341. Postpartum depression: do we still need this diagnostic term?
  342. Gruppentherapie bei Depression in der frühen Mutterschaft
  343. Neuropsychological and neurophysiological findings in individuals suspected to be at risk for schizophrenia: preliminary results from the Basel early detection of psychosis study - Früherkennung von Psychosen (FEPSY)
  344. Östrogene und gonadale Achse Implikationen für die Therapie von Frauen mit Schizophrenien
  345. Oestrogens and schizophrenia
  346. Controversial issues in climacteric medicine III: Hormone replacement therapy in climacteric and aging brain
  347. Oestrogens and schizophrenia - Introduction
  348. Oestrogen effects in schizophrenia and their potential therapeutic implications - Review
  349. Östrogene und Schizophrenie - Patientinnen an der Schnittstelle zwischen Psychiatrie und Gynäkologie
  350. Estrogen effects in schizophrenia — brief update and potential therapeutic implications
  351. Group therapy for mothers with depression
  352. Sexualhormone und Psyche
  353. Innentitel
  354. 1 Einfluss von Östrogenen und Gestagenen auf das Zentralnervensystem
  355. 2 Das prämenstruelle Syndrom
  356. 5 Östrogene und schizophrene Psychosen
  357. 4 Hormonelle Aspekte bei affektiven Störungen, Angstund Zwangserkrankungen
  358. 6 Einfluss von Psychopharmaka auf Reproduktion und Kontrazeption
  359. 7 Sachverzeichnis
  360. Einführung: Sexualhormone und Psyche – Ergebnisse des 2. Interdisziplinären Frankfurter Gesprächs zur Kontrazeption
  361. 3 Postpartale Depression und depressive Zustände im Klimakterium sowie unter der Hormonsubstitution
  362. Schizophrenie und Wahn im höheren und hohen Lebensalter
  363. Geschlechtsunterschiede bei Schizophrenie - m�gliche therapeutische Implikationen
  364. Gruppentherapie f�r depressive M�tter
  365. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry
  366. Book Reviews
  367. Psychische Erkrankungen bei Frauen - einige Argumente für eine geschlechtersensible Psychiatrie und Psychotherapie/ Mental diseases in women - some arguments for a gender-sensitive psychiatry and psychotherapy
  368. Association between oestradiol and puerperal psychosis
  369. Computer-assisted self-monitoring by patients with schizophrenia
  370. Traditional Methodology and Outcome Assessment in Studies on the Course of Schizophrenia
  371. Visual cognitive deficits in patients with borderline personality disorder
  372. The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective
  373. The ABC schizophrenia study: a preliminary overview of the results
  374. Gonadal function and its influence on psychopathology
  375. Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life-cycle
  376. Causes and Consequences of the Gender Difference in Age at Onset of Schizophrenia
  377. What do we really know about late-onset schizophrenia?
  378. 50 Jahre nach Manfred Bleuler
  379. Psychische Störungen und Erkrankungen nach der Entbindung
  380. Changing patterns of mental health care in Germany
  381. Late onset schizophrenia — A valid entity? An empirical study on risk factors, psychopathology and course
  382. Case management for schizophrenic patients at risk for rehospitalization: A case control study
  383. Symptom Assessment in Casenotes and the Clinical Diagnosis of Schizophrenia
  384. Late-onset Schizophrenia and Late Paraphrenia
  385. Onset and Early Course of Schizophrenia
  386. Further evidence for a specific role of estradiol in schizophrenia?
  387. Validation of Danish case register diagnosis for schizophrenia
  388. Wilhelm Griesinger and the Concept of Community Care in 19th-Century Germany
  389. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia
  390. Organic factors and the clinical features of late paranoid psychosis: a comparison with Alzheimer's disease and normal ageing
  391. The Epidemiology of Early Schizophrenia
  392. Wirken Östrogene antipsychotisch?
  393. Can Estradiol Modulate Schizophrenic Symptomatology?
  394. Higher morbidity risk for schizophrenia in males: Fact or fiction?
  395. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia
  396. Schizophrenia and oestrogens — is there an association?
  397. Compulsory admission of psychiatric patients – an international comparison
  398. Einfluß des Menstruationszyklus auf die therapeutische Ansprechbarkeit schizophrener Patientinnen
  399. Schizophrenie — Eine Krankheit verliert ihre Dämonie
  400. The influence of age and sex on the onset and early course of schizophrenia
  401. Does case management reduce the rehospitalization rate?
  402. Die Zwangseinweisung psychiatrischer Patienten im nationalen und internationalen Vergleich - Häufigkeiten und Einflußfaktoren
  403. Is age of onset in schizophrenia influenced by marital status?
  404. First onset and early symptomatology of schizophrenia
  405. IRAOS: an instrument for the assessment of onset and early course of schizophrenia
  406. Schizophrenic symptomatology varies with serum estradiol levels during menstrual cycle
  407. Effects of the Menstrual Cycle on the Therapeutic Response in Schizophrenia
  408. Effects of the menstrual cycle on therapeutic response in schizophrenic patients
  409. Interview "Onset of Schizophrenia"
  410. Geschlechtsunterschiede bei schizophrenen Erkrankungen
  411. Factors influencing compulsory admission of psychiatric patients
  412. Différences selon le sexe dans l’âge d’apparition, la symptomatologie et l’évolution de la schizophrénie
  413. 15 Jahre Psychiatriereform in der Bundesrepublik Deutschland
  414. Community care in child psychiatry
  415. Gender Differences in Age at Onset and Course of Schizophrenic Disorders
  416. How does gender influence age at first hospitalization for schizophrenia? A transnational case register study
  417. Schizophrenia — a disease of young single males?
  418. Central Institute of Mental Health, Mannheim, West Germany
  419. Was ist postpartale Depression?
  420. Estrogens and Schizophrenia
  421. Early Detection of Psychosis - Helpful or Stigmatizing Experience for Those Concerned?
  422. Early Detection and Intervention in Psychosis
  423. Neurocognition and Motor Functioning in the Prediction of Psychosis